Related Experiment Video

Updated: Mar 20, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine

Michel E Bertrand1, Charalambos Vlachopoulos2, Jean-Jacques Mourad3

  • 1Lille Heart Institute, 139 C-76 rue de Lille Lambersart, 59037, Lille, France. mbertrand2007@gmail.com.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|June 4, 2016
PubMed

Insights

Combining statins, ACE inhibitors, and CCBs significantly reduces cardiovascular events in high-risk patients. Triple therapy offers an effective approach to managing global cardiovascular risk, improving outcomes for coronary artery disease patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Coronary artery disease (CAD) management is complex, involving multiple risk factors like hypertension and hypercholesterolemia.
  • Statins, ACE inhibitors, and calcium channel blockers (CCBs) are cornerstone therapies for cardiovascular risk reduction.
  • Current guidelines advocate a comprehensive approach to managing cardiovascular risk factors.

Purpose of the Study:

  • To review the evidence supporting the combination of statins, ACE inhibitors, and CCBs in hypertensive patients with hypercholesterolemia or CAD.
  • To evaluate the efficacy of triple therapy in reducing major adverse cardiovascular events.
  • To explore the benefits of single-pill formulations for treatment adherence.

Main Methods:

  • Literature search for studies combining statins with antihypertensive drugs in patients with hypertension and hypercholesterolemia or stable CAD.
  • Analysis of existing trial data, including a post hoc analysis from the EUROPA trial.
  • Review of evidence on the impact of combination therapy on cardiovascular event reduction and patient adherence.

Main Results:

  • Triple therapy with statins, ACE inhibitors, and CCBs is associated with a significant reduction in major cardiovascular events.
  • A post hoc analysis of the EUROPA trial showed a 46% reduction in cardiovascular death, myocardial infarction, or resuscitated cardiac arrest with triple therapy.
  • Single-pill formulations combining these drug classes enhance treatment adherence.

Conclusions:

  • Triple therapy with statins, ACE inhibitors, and CCBs is an effective strategy for managing global cardiovascular risk in high-risk patients.
  • This combination therapy offers significant benefits in reducing cardiovascular events for patients with CAD.
  • Single-pill formulations represent a promising approach to improve patient adherence and therapeutic outcomes.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
569
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
515
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
377
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
398
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K